Skip to main content
Top
Published in: BMC Nephrology 1/2024

Open Access 05-01-2024 | Hyperparathyroidism | Case Report

The refractory secondary hyperparathyroidism presenting with retro-orbital brown tumor: a case report

Authors: Cihan Uysal, Tugba Yilmaz, Hamiyet Ozkan, Ozlem Canoz, Bulent Tokgoz

Published in: BMC Nephrology | Issue 1/2024

Login to get access

Abstract

Background

Tertiary hyperparathyroidism describes the autonomous and excessive secretion of parathyroid hormone (PTH) by the parathyroid glands after longstanding secondary hyperparathyroidism in chronic kidney disease. Brown tumors are a sign of uncontrolled hyperparathyroidism. In this case, we have reported a refractory and destructive hyperparathyroidism storm. Also, it presented with atypical onset and unexpected adenoma location.

Case presentation

A 37-year-old man was diagnosed with end-stage kidney disease 22 years ago. He has been undergoing dialysis treatment since that time. Recently, he was admitted to the ophthalmology department due to the unilateral anterior bulging of the right eye and drooping of the eyelid. Magnetic resonance imaging exhibited an extraconal mass lesion located in the right orbital posterior superolateral position. Computerized tomography scans considered expansile bone lesion with peripheral calcification and originating from the sphenoid wing. The bone mass lesion was resected via craniotomy due to the compressive effect. The pathological findings were consistent with brown tumors. Plasma intact PTH level was 4557 pg/mL. The patient informed that he underwent parathyroidectomy and two leg fractures operation in a medical query. Parathyroid scintigraphy determined three distinct foci consistent with adenomas and one of them was in mediastenum. Second parathyroidectomy was recommended to the patient but the patient refused surgery. Despite his medication and dialysis regimen being revised, PTH levels were maintained at higher levels in follow-up.

Conclusions

We presented a hyperparathyroidism case that was resistant to all treatments and exhibited all the severe complications in a long-term dialysis patient. Furthermore, this case has revealed the importance and difficulty of secondary hyperparathyroidism management.
Literature
1.
go back to reference Brown EM. Control of parathyroid hormone secretion by its key physiological regulators. San Diego, CA: Academic Press; 2015.CrossRef Brown EM. Control of parathyroid hormone secretion by its key physiological regulators. San Diego, CA: Academic Press; 2015.CrossRef
2.
go back to reference Saliba W, El-Haddad B. Secondary hyperparathyroidism: pathophysiology and treatment. J Am Board Family Med. 2009;22(5):574–81.CrossRef Saliba W, El-Haddad B. Secondary hyperparathyroidism: pathophysiology and treatment. J Am Board Family Med. 2009;22(5):574–81.CrossRef
3.
go back to reference Palumbo V, Damiano G, Fazzotta S, Messina M, Monte AL, Monte GL. Tertiary hyperparathyroidism: a review. Clin Ter 2021, 172(3). Palumbo V, Damiano G, Fazzotta S, Messina M, Monte AL, Monte GL. Tertiary hyperparathyroidism: a review. Clin Ter 2021, 172(3).
4.
go back to reference Denda M, Finch J, Slatopolsky E. Phosphorus accelerates the development of parathyroid hyperplasia and secondary hyperparathyroidism in rats with renal failure. Am J Kidney Dis. 1996;28(4):596–602.CrossRefPubMed Denda M, Finch J, Slatopolsky E. Phosphorus accelerates the development of parathyroid hyperplasia and secondary hyperparathyroidism in rats with renal failure. Am J Kidney Dis. 1996;28(4):596–602.CrossRefPubMed
5.
go back to reference de Boer IH, Gorodetskaya I, Young B, Hsu C-y, Chertow GM. The severity of secondary hyperparathyroidism in chronic renal insufficiency is GFR-dependent, race-dependent, and associated with cardiovascular disease. J Am Soc Nephrol. 2002;13(11):2762–9.CrossRefPubMed de Boer IH, Gorodetskaya I, Young B, Hsu C-y, Chertow GM. The severity of secondary hyperparathyroidism in chronic renal insufficiency is GFR-dependent, race-dependent, and associated with cardiovascular disease. J Am Soc Nephrol. 2002;13(11):2762–9.CrossRefPubMed
6.
go back to reference Proimos E, Chimona TS, Tamiolakis D, Tzanakakis MG, Papadakis CE. Brown tumor of the maxillary sinus in a patient with primary hyperparathyroidism: a case report. J Med Case Rep. 2009;3:7495.CrossRefPubMed Proimos E, Chimona TS, Tamiolakis D, Tzanakakis MG, Papadakis CE. Brown tumor of the maxillary sinus in a patient with primary hyperparathyroidism: a case report. J Med Case Rep. 2009;3:7495.CrossRefPubMed
7.
go back to reference Moe S, Drüeke T, Cunningham J, Goodman W, Martin K, Olgaard K, Ott S, Sprague S, Lameire N, Eknoyan G. Definition, evaluation, and classification of renal osteodystrophy: a position statement from kidney disease: improving global outcomes (KDIGO). Kidney Int. 2006;69(11):1945–53.CrossRefPubMed Moe S, Drüeke T, Cunningham J, Goodman W, Martin K, Olgaard K, Ott S, Sprague S, Lameire N, Eknoyan G. Definition, evaluation, and classification of renal osteodystrophy: a position statement from kidney disease: improving global outcomes (KDIGO). Kidney Int. 2006;69(11):1945–53.CrossRefPubMed
8.
go back to reference Komaba H, Kakuta T, Fukagawa M. Management of secondary hyperparathyroidism: how and why? Clin Exp Nephrol. 2017;21:37–45.CrossRefPubMed Komaba H, Kakuta T, Fukagawa M. Management of secondary hyperparathyroidism: how and why? Clin Exp Nephrol. 2017;21:37–45.CrossRefPubMed
9.
go back to reference Baracaldo RM, Bao D, Iampornpipopchai P, Fogel J, Rubinstein S. Facial disfigurement due to osteitis fibrosa cystica or brown tumor from secondary hyperparathyroidism in patients on dialysis: a systematic review and an illustrative case report. Hemodial Int. 2015;19(4):583–92.CrossRefPubMed Baracaldo RM, Bao D, Iampornpipopchai P, Fogel J, Rubinstein S. Facial disfigurement due to osteitis fibrosa cystica or brown tumor from secondary hyperparathyroidism in patients on dialysis: a systematic review and an illustrative case report. Hemodial Int. 2015;19(4):583–92.CrossRefPubMed
10.
go back to reference Tarrass F, Benjelloun M, Bensaha T. Severe jaw enlargement associated with uremic hyperparathyroidism. Hemodial Int Int Symp Home Hemodial. 2008;12(3):316–8.CrossRef Tarrass F, Benjelloun M, Bensaha T. Severe jaw enlargement associated with uremic hyperparathyroidism. Hemodial Int Int Symp Home Hemodial. 2008;12(3):316–8.CrossRef
11.
go back to reference Tayfun H, Metin O, Hakan S, Zafer B, Vardar A. Brown tumor as an unusual but preventable cause of spinal cord compression: case report and review of the literature. Asian J Neurosurg. 2014;9(01):40–4.CrossRefPubMed Tayfun H, Metin O, Hakan S, Zafer B, Vardar A. Brown tumor as an unusual but preventable cause of spinal cord compression: case report and review of the literature. Asian J Neurosurg. 2014;9(01):40–4.CrossRefPubMed
12.
go back to reference Levine MR, Chu A, Abdul-Karim FW. Brown tumor and secondary hyperparathyroidism. Archives of Ophthalmology (Chicago Ill: 1960). 1991;109(6):847–9.CrossRefPubMed Levine MR, Chu A, Abdul-Karim FW. Brown tumor and secondary hyperparathyroidism. Archives of Ophthalmology (Chicago Ill: 1960). 1991;109(6):847–9.CrossRefPubMed
13.
go back to reference Zwick OM, Vagefi MR, Cockerham KP, McDermott MW. Brown tumor of secondary hyperparathyroidism involving the superior orbit and frontal calvarium. Ophthalmic Plast Reconstr Surg. 2006;22(4):304–6.CrossRefPubMed Zwick OM, Vagefi MR, Cockerham KP, McDermott MW. Brown tumor of secondary hyperparathyroidism involving the superior orbit and frontal calvarium. Ophthalmic Plast Reconstr Surg. 2006;22(4):304–6.CrossRefPubMed
14.
go back to reference Gonzalez-Martínez E, Santamarta-Gómez D, Varela-Rois P, García-Cosamalón J. Brown tumor of the orbital roof as an initial and isolated manifestation of secondary hyperparathyroidism. Orbit. 2010;29(5):278–80.CrossRefPubMed Gonzalez-Martínez E, Santamarta-Gómez D, Varela-Rois P, García-Cosamalón J. Brown tumor of the orbital roof as an initial and isolated manifestation of secondary hyperparathyroidism. Orbit. 2010;29(5):278–80.CrossRefPubMed
15.
go back to reference KDIGO. 2017 Clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney international supplements 2017, 7(1):1–59. KDIGO. 2017 Clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney international supplements 2017, 7(1):1–59.
16.
go back to reference K/DOQI clinical. Practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Diseases: Official J Natl Kidney Foundation. 2003;42(4 Suppl 3):1–201. K/DOQI clinical. Practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Diseases: Official J Natl Kidney Foundation. 2003;42(4 Suppl 3):1–201.
17.
go back to reference Palmer SC, Nistor I, Craig JC, Pellegrini F, Messa P, Tonelli M, Covic A, Strippoli GF. Cinacalcet in patients with chronic kidney disease: a cumulative meta-analysis of randomized controlled trials. PLoS Med. 2013;10(4):e1001436.CrossRefPubMedPubMedCentral Palmer SC, Nistor I, Craig JC, Pellegrini F, Messa P, Tonelli M, Covic A, Strippoli GF. Cinacalcet in patients with chronic kidney disease: a cumulative meta-analysis of randomized controlled trials. PLoS Med. 2013;10(4):e1001436.CrossRefPubMedPubMedCentral
18.
go back to reference Mazzaferro S, Pasquali M, Farcomeni A, Vestri AR, Filippini A, Romani AM, Barresi G, Pugliese F. Parathyroidectomy as a therapeutic tool for targeting the recommended NKF-K/DOQI ranges for serum calcium, phosphate and parathyroid hormone in dialysis patients. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association-Eur Ren Association. 2008;23(7):2319–23. Mazzaferro S, Pasquali M, Farcomeni A, Vestri AR, Filippini A, Romani AM, Barresi G, Pugliese F. Parathyroidectomy as a therapeutic tool for targeting the recommended NKF-K/DOQI ranges for serum calcium, phosphate and parathyroid hormone in dialysis patients. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association-Eur Ren Association. 2008;23(7):2319–23.
19.
go back to reference Moorthi RN, Moe SM. CKD-mineral and bone disorder: core curriculum 2011. Am J Kidney Diseases: Official J Natl Kidney Foundation. 2011;58(6):1022–36.CrossRef Moorthi RN, Moe SM. CKD-mineral and bone disorder: core curriculum 2011. Am J Kidney Diseases: Official J Natl Kidney Foundation. 2011;58(6):1022–36.CrossRef
20.
go back to reference Ho LY, Wong PN, Sin HK, Wong YY, Lo KC, Chan SF, Lo MW, Lo KY, Mak SK, Wong AK. Risk factors and clinical course of hungry bone syndrome after total parathyroidectomy in dialysis patients with secondary hyperparathyroidism. BMC Nephrol. 2017;18(1):12.CrossRefPubMedPubMedCentral Ho LY, Wong PN, Sin HK, Wong YY, Lo KC, Chan SF, Lo MW, Lo KY, Mak SK, Wong AK. Risk factors and clinical course of hungry bone syndrome after total parathyroidectomy in dialysis patients with secondary hyperparathyroidism. BMC Nephrol. 2017;18(1):12.CrossRefPubMedPubMedCentral
21.
go back to reference Stracke S, Keller F, Steinbach G, Henne-Bruns D, Wuerl P. Long-term outcome after total parathyroidectomy for the management of secondary hyperparathyroidism. Nephron Clin Pract. 2009;111(2):c102–109.CrossRefPubMed Stracke S, Keller F, Steinbach G, Henne-Bruns D, Wuerl P. Long-term outcome after total parathyroidectomy for the management of secondary hyperparathyroidism. Nephron Clin Pract. 2009;111(2):c102–109.CrossRefPubMed
Metadata
Title
The refractory secondary hyperparathyroidism presenting with retro-orbital brown tumor: a case report
Authors
Cihan Uysal
Tugba Yilmaz
Hamiyet Ozkan
Ozlem Canoz
Bulent Tokgoz
Publication date
05-01-2024
Publisher
BioMed Central
Published in
BMC Nephrology / Issue 1/2024
Electronic ISSN: 1471-2369
DOI
https://doi.org/10.1186/s12882-024-03455-8

Other articles of this Issue 1/2024

BMC Nephrology 1/2024 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.